* MediciNova Inc MNOV.OQ MNOV.O is expected to show no
change
in quarterly revenue when it reports results on February 13
(estimated) for the period ending December 31 2024
*
* LSEG's mean analyst estimate for MediciNova Inc is for a
loss
of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MediciNova
Inc is
$9.00, above its last closing price of $1.87.
This summary was machine generated February 11 at 21:23 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)